Form 4: Cingulate EVP and COO Laurie Myers Granted 31,000 Stock Options

Cingulate Inc.'s Executive Vice President and Chief Operating Officer, Laurie Myers, was granted 31,000 stock options with an exercise price of $4.42, vesting over a four-year period.

Summary

• Laurie Myers, the Executive Vice President and Chief Operating Officer of Cingulate Inc., was granted 31,000 stock options.
• The stock options have an exercise price of $4.42 per share.
• The options were granted on July 7, 2025, and are set to expire on July 7, 2035.
• Vesting for these options will occur in two phases: 25% on the one-year anniversary of the grant date (July 7, 2026), and the remaining shares will vest in substantially equal monthly installments over the subsequent 36-month period.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's financial interests with the long-term performance of the company and shareholder value creation. It indicates a commitment to retaining and incentivizing leadership.

Positives

• The grant of stock options to a key executive like the EVP and COO aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the executive.

Future Outlook

The document details the vesting schedule for the granted stock options, indicating that 25% will vest on July 7, 2026, with the remainder vesting monthly over the subsequent 36 months, aligning executive incentives with future company performance.

Industry Context

This filing is a standard disclosure of an insider transaction, specifically the grant of stock options as part of executive compensation. Such grants are common practice across various industries to incentivize management and align their financial interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to key executives is a common component of compensation packages in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where long-term development cycles necessitate sustained executive commitment.
• The vesting schedule, with an initial cliff vesting followed by monthly installments over three years, is a typical structure designed to retain executives and ensure continued performance over time, comparable to practices at companies like Moderna or BioNTech for their R&D leadership.

Stakeholder Impact

• Shareholders: The grant of options can align executive incentives with shareholder interests, potentially leading to improved long-term performance. However, future exercise of options could lead to minor share dilution.
• Employees (specifically Laurie Myers): This represents a significant component of her compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will begin vesting with 25% on July 7, 2026.
• The remaining options will vest in substantially equal monthly installments over the 36-month period following the initial vesting date.

Key Dates

Keywords

Cingulate Inc., CING, stock options, executive compensation, insider transaction, beneficial ownership, Form 4